Loading...

Daily news and top headlines for life science research professionals

FREE Email Newsletter View Sample


Lonza Signs Light Path Discovery Agreement with LegoChem Biosciences to Provide Pre-clinical Material of Novel Therapeutic Compound

Featured In: Supplier News

Wednesday, March 7, 2024

See today's top life science stories and headlines - Sign up now!

newsvine diigo google
slashdot
Share
Loading...

Lonza announced an agreement with Korean Biotech, LegoChem Biosciences, for the custom material production of a monoclonal antibody that will be used for in vivo proof of concept studies for their technology platform development. Under this agreement, Lonza will produce pre-clinical material using Light Path Discovery Services at its applied protein services facility in Cambridge, UK.

“Lonza’s Light Path Discovery Services were specifically designed with the demands of pre-clinical assessment in mind,” said Janet White, Head of Lonza’s Development Services. “Lonza has built a strong reputation for CMO excellence. Today, we’re also focusing efforts on supporting emerging biotechnology innovation at every stage of development to allow each customer the best chance for clinical success.”

Woo, Sung Ho, Ph.D., Biology Director/Senior Vice President of LegoChem Biosciences said, “We have chosen to work with Lonza on this important project because of their reliability and solid reputation in field of mammalian development.”

Lonza’s Light Path Custom Material Services supports projects in their early phase, providing cGMP product within 11 months. In addition, Lonza’s Light Path Discovery Service provides non-GMP product in 6 to 10 weeks, to support customers in the discovery testing phase. Since the launch of Light Path in early 2011, Lonza has seen an increased demand for this unique offering focused on a reduced timeline to IND filing. Light Path allows customers to reach their clinical milestones more efficiently.

Source: Lonza

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Live Cell Analysis of Autophagy

Analysis of autophagosome formation using fluorescent cellular imaging and lentiviral biosensors.

Deconstructing 3D Cell Culture

3D culture models offer the potential to significantly reduce drug failure.

Safety Without Sacrifice

Safety Without Sacrifice

Liquid handling ergonomics and performance considerations

ELNs: The Beating Heart of a Scientist’s World

ELNs: The Beating Heart of a Scientist’s World

As ELNs deliver more benefits to researchers, the cost of changing working practice is outweighed by access to high quality, high context collaboration.

Evaluation of a New Nano-Type UV-Vis Spectrophotometer

Analysis of one- to four-microliter size samples for nucleic acids has become routine in many life science laboratories. However, until now, available instruments require considerable manipulation of the instrument and sample; some require manually recording the data. The user must typically lower and raise the arm manually, then wipe the sample manually from the target after each analysis. And fiberoptics used in some of these instruments are subject to deterioration.

Production of Recombinant Proteins and Monoclonal Antibodies in Hollow Fiber Bioreactors

While well-understood, robust and convenient, classical batch-style 2-D culture on non-porous supports or 3-D suspension culture in other devices are really not very biologically relevant models. Cell culture conditions can affect the quality of the antibody or protein produced.

Selecting Robots for Use in Drug Discovery and Testing

Drug discovery and testing, with their need for speed, repeatability and verification, are ideally suited to benefit from robot automation. It is therefore not surprising that robots have been at the forefront of automation developments in both these areas.

HP Scalable Network Storage Systems for Life Sciences

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
Loading...

Free Life Science Industry
Subscriptions

Magazine

wireless week

Newsletters

newsletters

Sign up now



MULTIMEDIA

Video:

Epigenetics

Aug 30

Hank & his clone Circus Hank explain the power of epigenetics, which studies the factors that determine how much or whether some genes are expressed in your body.

Podcasts:

Futures In Biotech 93: Snyder's Omics

May 17

Host: Marc Pelletier Co-Host: Andre Nantel, Ph.D. The technologies that our guest has developed are playing an important role in changing the world, not like the car, the microwave and the cell phone, but as in Drs. Flox, McCoy, and Crusher. Guest: Dr. Michael Snyder We invite...

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter

Information: